Antibodies

15 June 2017

Novartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years

15 June 2017

Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102

14 June 2017

Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs

14 June 2017

MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent

14 June 2017

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

14 June 2017

Celltrion Healthcare showcases data supporting the efficacy and safety of Truxima® (CT-P10, biosimilar rituximab) in advanced follicular lymphoma and rheumatoid arthritis

14 June 2017

Alpine Immune Sciences Announces Presentation of Preclinical Data Showing Potency of Its First-Generation Dual ICOS and CD28 Antagonist vIgDs in an Animal Model

14 June 2017

Phase 1 Clinical Study Results of REMD Biotherapeutics’ Lead Product Candidate, REMD-477, Demonstrate Reduced Need for Insulin and Improved Blood Glucose Levels for Patients with Type 1 Diabetes

13 June 2017

New Study Shows Patients Treated With CroFab® Have Improved Recovery From Copperhead Envenomation

13 June 2017

FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy

13 June 2017

Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies

13 June 2017

Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma

12 June 2017

Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly

12 June 2017

Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia

12 June 2017

Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 topre-clinical development

11 June 2017

Lilly’s Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS

9 June 2017

Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer

7 June 2017

Teva’s Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention

6 June 2017

AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research

6 June 2017

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

6 June 2017

Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer

6 June 2017

TRACON Pharmaceuticals Presents Positive Clinical Data from TRC105 and TRC102 Studies at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

6 June 2017

Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting

6 June 2017

AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting

5 June 2017

BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting

5 June 2017

Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting

5 June 2017

Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma

5 June 2017

New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

5 June 2017

Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models

5 June 2017

Aridis Pharmaceuticals, Inc. Presents Positive Phase 2a Safety and Efficacy Data of Salvecin™ (AR-301) in Patients with Severe Pneumonia Caused by Staphylococcus aureus During the 2017 ASM Microbe Congress

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: “Drug the Undruggable” Technologies

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription